Introduction {#section5-2050312113519986}
============

Patients with abdominal aortic aneurysm (AAA) have an increased cardiovascular mortality.^[@bibr1-2050312113519986]^ Careful preoperative patient selection is therefore important,^[@bibr2-2050312113519986],[@bibr3-2050312113519986]^ taking into account risk factors for atherosclerosis balanced against the risk of aneurysm rupture.^[@bibr4-2050312113519986][@bibr5-2050312113519986][@bibr6-2050312113519986]--[@bibr7-2050312113519986]^ The Vascular Center in Malmö practices an individual evaluation by a specialist in vascular medicine prior to both elective fenestrated endovascular aneurysm repair (FEVAR) and standard endovascular aneurysm repair (EVAR). The major aims of this assessment are evaluation of eligibility^[@bibr8-2050312113519986],[@bibr9-2050312113519986]^ for surgery from a medical perspective, identification of previously unknown medical illness, and pharmacological optimization, resulting in lower preoperative costs and a pharmacological optimization.^[@bibr10-2050312113519986]^ The FEVAR method enables surgical treatment in a patient group that, because of comorbidities, may not be suitable for open repair.^[@bibr11-2050312113519986][@bibr12-2050312113519986][@bibr13-2050312113519986]--[@bibr14-2050312113519986]^ In comparison with patients treated with EVAR, however, patients who require FEVAR have a more advanced aneurysm disease, and the FEVAR method is also a more technically demanding procedure that may be associated with a higher risk of perioperative morbidity and mortality.^[@bibr11-2050312113519986]^ The larger extent of aneurysmal disease in FEVAR patients per se may also perhaps indicate a higher burden of generalized atherosclerosis associated with a decreased mid-term survival. Hence, a more stringent preoperative patient selection in the FEVAR group might therefore be motivated. To elucidate these questions, we have evaluated differences in comorbidities, age, medication, and mortality in patients undergoing elective FEVAR and EVAR.

Methods {#section6-2050312113519986}
=======

Patients {#section7-2050312113519986}
--------

The Vascular Center Malmö-Lund is a tertiary referral center for patients with vascular disease. Patient data were retrieved from the prospective database for endovascular interventions and from patient records. This study comprised consecutive patients undergoing elective FEVAR for complex (juxtarenal) nonruptured AAA (Zenith^®^ stent grafts; Cook Europe A/S, Bjaeverskov, Denmark) (n = 81), and standard EVAR (Zenith stent grafts; Cook Europe A/S) for infrarenal nonruptured AAA (n = 201), between February 2007 and May 2011 ([Figure 1](#fig1-2050312113519986){ref-type="fig"}). Necks \< 8 mm in length, conical in shape (\>15% diameter change/10 mm) or heavily thrombus lined were common indications for FEVAR. The fenestrated stent graft is a modular stent graft with fenestrations, sometimes with a scallop, located on the most proximal tubular portion of the stent graft. Fenestrations were designed to match the locations of the target visceral artery ostia. The target visceral arteries were catheterized through the fenestrations after partial deployment of the proximal tubular graft using access from the contralateral common femoral artery. The stent graft repair was then completed by extension with a bifurcated main body stent graft overlapping into the tubular stent graft and extension stent graft limbs into the iliac arteries bilaterally.^[@bibr15-2050312113519986]^ During the study period, target visceral arteries were routinely stent grafted through the fenestrations and scallops. Prior to operation, a specialist in vascular medicine evaluated patient eligibility for surgical intervention in both groups in accordance with recommendations from the European Society of Cardiology,^[@bibr16-2050312113519986]^ concerning hypertension, cardiopulmonary, and renal function deficits. Antiatherosclerotic and antihypertensive medication was evaluated and optimized in each patient. Simvastatin was provided 40 mg once daily to reach recommended target values.^[@bibr17-2050312113519986]^ Metoprolol was given 50 mg once daily in the absence of contraindications such as bradycardia, atrioventricular (AV) block, or severe obstructive pulmonary disease. Echocardiography, spirometry, cardiopulmonary exercise testing, or stress echocardiography were performed in selected cases according to recommendations.^[@bibr16-2050312113519986]^ Two out of 83 (2.4%) FEVAR patients were excluded from analysis because preoperative evaluation was impossible due to emergency operation, and 23 of 224 (10.3%) EVAR patients were excluded from the comparative analysis because preoperative evaluation had not been performed. The Research Ethics Committee, University of Lund, granted an ethical approval of this study (2012/638).

![Flow chart over operations for aorto-iliac aneurysms and dissections during the study period.\
EVAR: endovascular aneurysm repair.\
\*Two emergency cases.\
\#Eight pseudoaneurysms in the abdominal aorta, one additional embolization to the inferior mesenteric artery, three not evaluated by a vascular physician prior to EVAR.](10.1177_2050312113519986-fig1){#fig1-2050312113519986}

Electrocardiography {#section8-2050312113519986}
-------------------

Preoperative electrocardiography (ECG) at rest was performed to evaluate signs of atrial fibrillation and myocardial ischemia. Myocardial ischemia on ECG was defined as presence of pathological Q/QS patterns, deep or moderate T-wave inversion, ST-segment depression, or complete left bundle branch block.^[@bibr18-2050312113519986],[@bibr19-2050312113519986]^

Echocardiography {#section9-2050312113519986}
----------------

As part of the preoperative evaluation, transthoracic echocardiographic examinations were carried out with Sonos 2500 or Sonos 5500 (Philips, Eindhoven, the Netherlands). Left ventricular ejection fraction (EF) was assessed visually by qualified personal.^[@bibr20-2050312113519986],[@bibr21-2050312113519986]^ EF was graded either as normal (≥ 55%), mildly (45%−50%), moderately (35%−40%), or severely reduced (\<35%).^[@bibr20-2050312113519986],[@bibr21-2050312113519986]^

Evaluation of renal function {#section10-2050312113519986}
----------------------------

Glomerular filtration rate (GFR) was calculated in accordance with the Cockroft--Gault formula taking into account serum creatinine, age, weight, and gender.^[@bibr22-2050312113519986]^ The National Kidney Foundation guidelines were used, grading GFR levels for different stages of chronic kidney disease:^[@bibr23-2050312113519986],[@bibr24-2050312113519986]^ Stage I defined as GFR \> 90 mL/min/1.73 m^2^ (normal or increased GFR), stage II as GFR 60--89 mL/min/1.73 m^2^ (minute decrease in GFR), stage III as GFR 30--59 mL/min/1.73 m^2^ (moderate decrease in GFR), stage IV as GFR 15--29 mL/min/1.73 m^2^ (substantial decrease in GFR), and stage V as GFR \< 15 mL/min/1.73 m^2^ (end-stage renal disease in need of dialysis).

Spirometry {#section11-2050312113519986}
----------

Spirometry was performed in accordance with the European Respiratory Society standards.^[@bibr25-2050312113519986]^ The majority of the spirometries were performed at the Vascular Center in Malmö. The spirometer (Microlab 3000 or EasyOne; Microlab 3000, CareFusion, Hoechberg, Germany, and EasyOne, ndd Medical Technologies, Inc., Andover, MA, USA) was utilized under the supervision of a physiotherapist, measuring forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC). FEV~1~% was defined as the percentage of measured-to-predicted normal FEV~1~, and FVC% as measured-to-predicted normal FVC.^[@bibr26-2050312113519986][@bibr27-2050312113519986]--[@bibr28-2050312113519986]^ The Global Initiative for Chronic Obstructive Lung Diseases (GOLD) guidelines were used to evaluate the presence and severity of chronic obstructive pulmonary disease (COPD).^[@bibr29-2050312113519986]^ COPD was defined as present if FEV~1~/FVC \< 70% (age \< 65 years) or FEV~1~/FVC \< 65% (age ≥ 65 years). Stage 1 (mild) was defined as FEV~1~ ≥ 80%, stage 2 (moderate) as FEV~1~ ≥ 50% to \<80%, stage 3 (severe) as FEV~1~ ≥ 30% to \<50%, and stage 4 (very severe) as FEV~1~ \< 30% of predicted value.

Follow-up {#section12-2050312113519986}
---------

All patients were monitored from operation until 1 May 2013 or until death. Median time of follow-up was 40 months (interquartile range (IQR): 28--61 months) in the FEVAR group and 43 months (IQR: 30--55 months) in the EVAR group. The Swedish Population Registry was used to retrieve mortality data.

Other definitions {#section13-2050312113519986}
-----------------

Cerebrovascular disease was defined as either a history of stroke (bleeding or infarction) or transient ischemic attack (TIA). Ischemic heart disease was defined as previous myocardial infarction, angina pectoris, coronary artery bypass grafting, or percutaneous coronary angioplasty. Diabetes mellitus was defined as ongoing antidiabetic treatment (diet, oral hypoglycemic agents, or insulin), and anemia as hemoglobin \< 134 g/L in men and \<117 g/L in women. The maximal AAA diameter was defined as the shortest transverse diameter of the AAA at its widest portion. Hypertension was defined as ongoing antihypertensive medication and uncontrolled hypertension as systolic blood pressure \> 140 mm Hg or diastolic blood pressure \> 90 mm Hg (systolic blood pressure \> 130 mm Hg or diastolic blood pressure \> 80 mm Hg in patients with diabetes mellitus). Active smoking was defined as current tobacco consumption or tobacco consumption \< 1 year before surgery.

Statistical methods {#section14-2050312113519986}
-------------------

SPSS 17.0 software (SPSS, Inc., Chicago, IL) was used for data managing and statistical analysis. Differences in proportions were evaluated using the chi-square test or Kendall tau-b test. Mann--Whitney U tests were used when comparing groups using continuous variables. Survival curves for groups 1 and 2 were constructed according to the Kaplan--Meier method and Life table analysis. Log rank test was used in the overall comparison of survival curves. A multivariate Cox regression analysis was performed for identification of independent variables associated with mid-term mortality and expressed as hazard ratio (HR) with 95% confidence interval (CI). P \< 0.05 was considered as significant.

Results {#section15-2050312113519986}
=======

Comparison of patient characteristics between groups {#section16-2050312113519986}
----------------------------------------------------

Patients in the FEVAR group (median age: 72 years (IQR: 67--75 years)) were significantly younger than the EVAR group (75 years (IQR: 69--78 years), p = 0.006). There was no significant difference between the two groups concerning gender, smoking, or age of 80 years and above ([Table 1](#table1-2050312113519986){ref-type="table"}).

###### 

Patient variables and comorbidities in patients undergoing FEVAR and EVAR.

  Variable                                FEVAR     EVAR          p-value
  --------------------------------------- --------- ------------- ---------
  Age ≥ 80 years                          9 (11)    38 (19)       0.11
  Women                                   18 (22)   30 (15)       0.14
  Arterial hypertension                   76 (94)   164 (82)      0.01
  Active smoking                          38 (47)   74/199 (37)   0.28
  Diabetes mellitus                       3 (4)     28 (14)       0.01
  Ischemic heart disease                  46 (57)   93 (46)       0.11
  Cerebrovascular disease                 14 (17)   34 (17)       0.94
  Peripheral arterial occlusive disease   11 (14)   34 (17)       0.49
  All patients                            81        201           

![](10.1177_2050312113519986-table1)

EVAR: endovascular aneurysm repair; FEVAR: fenestrated endovascular aneurysm repair.

Maximal aneurysm size was equal in the two groups (p = 0.15). The percentages of fenestrations for renal and superior mesenteric arteries and scallops for the celiac trunk in the FEVAR patients are shown in [Table 2](#table2-2050312113519986){ref-type="table"}.

###### 

Results of investigation prior to FEVAR and EVAR.

  Variable                                FEVAR        EVAR           p-value
  --------------------------------------- ------------ -------------- ---------
  Maximal aortic aneurysm diameter (mm)                               
   40--54                                 12 (15)      29 (14)        
   55--64                                 48 (59)      98 (49)        
   ≥65                                    21 (26)      74 (37)        0.15
  Number of stent graft fenestrations                                 
   Right renal artery                     77 (95)      --             
   Left renal artery                      74 (91)      --             
   Superior mesenteric artery             16 (20)      --             
   Truncus coeliacus (scallops)           5 (6)        --             --
  Electrocardiographic (ECG) findings                                 
   Ischemia                               41 (51)      77/190 (41)    0.10
   Atrial fibrillation                    4 (5)        18/197 (9.6)   0.24
  Echocardiographic findings                                          
   Ejection fraction staging                                          
    Normal                                40/58 (69)   96/125 (77)    
    Slightly decreased                    9/58 (16)    16/125 (13)    
    Moderately decreased                  4/58 (7)     7/125 (6)      
    Very decreased                        5/58 (9)     6/125 (5)      0.25
  Spirometric findings                                                
   COPD by definition                     15/33 (45)   59/121 (49)    0.78
  Stages of chronic kidney disease                                    
   Stage I                                16 (20)      46/198 (23)    
   Stage II                               33 (41)      72/198 (36)    
   Stage III                              29 (36)      70/198 (35)    
   Stage IV                               2 (2)        6/198 (3.0)    
   Stage V                                1 (1)        4/198 (2.0)    0.93
   Stage ≥ 3 chronic kidney disease       32 (40)      80/198 (40)    0.85
   Anemia                                 14 (17)      71 (35)        0.003
  All patients                            81           201            

![](10.1177_2050312113519986-table2)

EVAR: endovascular aneurysm repair; FEVAR: fenestrated endovascular aneurysm repair; COPD: chronic obstructive pulmonary disease.

A larger proportion of patients in the FEVAR group (n = 76 (94%)) had hypertension in comparison with the EVAR group (n = 164 (82%); p = 0.009). A larger proportion of the patients in the EVAR group (14%, n = 28) suffered from diabetes mellitus in comparison with the FEVAR group (n = 3 (4%); p = 0.013, [Table 1](#table1-2050312113519986){ref-type="table"}).

There was no difference between the groups in renal function (p = 0.47). A higher percentage of the patients in the EVAR group suffered from anemia, in comparison with the FEVAR group (n = 71 (35%) vs. n = 14 (17%); p = 0.003, [Table 2](#table2-2050312113519986){ref-type="table"}).

Comparison of patient medication between groups {#section17-2050312113519986}
-----------------------------------------------

At admission, there were no significant differences between the two groups regarding the proportions of patients with ongoing treatment with antiplatelet drugs, lipid-lowering agents, and vitamin K antagonists ([Table 3](#table3-2050312113519986){ref-type="table"}).

###### 

Medication at admission in patients undergoing FEVAR and EVAR.

  Variable                    FEVAR     EVAR       p-value
  --------------------------- --------- ---------- ---------
  Cardiovascular medication                        
   Any antiplatelet drug      69 (85)   174 (87)   0.76
   Lipid-lowering agent       77 (95)   183 (91)   0.26
   Vitamin K antagonist       9 (11)    17 (8.5)   0.49
  All patients                81        201        

![](10.1177_2050312113519986-table3)

EVAR: endovascular aneurysm repair; FEVAR: fenestrated endovascular aneurysm repair.

Comparison of reinterventions between groups {#section18-2050312113519986}
--------------------------------------------

There was no significant difference between the FEVAR and EVAR groups concerning reintervention rate (16/81 (20%) and 28/201 (14%); p = 0.22) or in the number of reinterventions performed per patient (p = 0.14).

Comparison of mortality between groups {#section19-2050312113519986}
--------------------------------------

There was no significant difference between the FEVAR and EVAR groups in crude 30-day (2/81 (2.5%) and 3/200 (1.5%); p = 0.56), 1-year (3/81 (3.7%) and 9/200 (4.5%); p = 0.77), and 2-year mortality (8/81 (9.9%) and 19/200 (9.5%); p = 0.92). Mid-term mortality at end of study was 16/81 (19.8%) in the FEVAR group and 48/200 (24.0%) in the EVAR group (p = 0.47, [Figure 2](#fig2-2050312113519986){ref-type="fig"}). When entering age, FEVAR or EVAR operation, diabetes mellitus, anemia, and hypertension in a Cox regression model, only age (HR: 1.07, 95% CI: 1.03--1.11; p \< 0.001) was found as an independent risk factor for mid-term mortality.

![Long-term survival for patients undergoing EVAR and FEVAR. Survival data are missing in one patient in the EVAR group. Numbers below axis denote the patients at risk at respective time point. Standard error of cumulative proportion of patient survival at end of interval is shown within parenthesis. The tick marks indicate censored data.\
EVAR: endovascular aneurysm repair; FEVAR: fenestrated endovascular aneurysm repair.](10.1177_2050312113519986-fig2){#fig2-2050312113519986}

Discussion {#section20-2050312113519986}
==========

The fact that risk of AAA rupture increases with maximal aneurysm diameter has to be weighed against the perioperative risk of surgery and mid-term outcome after endovascular therapy.^[@bibr5-2050312113519986],[@bibr30-2050312113519986]^ Because of the increased burden of overall cardiovascular morbidity in patients suffering from aortic aneurysm, careful patient selection and medical optimization prior to elective FEVAR and EVAR is of utmost importance.^[@bibr3-2050312113519986][@bibr4-2050312113519986]--[@bibr5-2050312113519986]^ This highlights the importance of current recommendations on control of cardiovascular risk factors in AAA patients, both before and after interventional treatment.^[@bibr31-2050312113519986]^ The present study demonstrated important differences in comorbidities and patient characteristics between the two groups. In comparison with the EVAR group, patients in the FEVAR group were younger and suffered to a lesser extent from diabetes mellitus and anemia. On the contrary, the FEVAR group had a higher proportion of patients with hypertension. The apparently more fit patients in the FEVAR group seems to reflect a more strict preoperative patient selection in the FEVAR group caused by a perceived increased risk of postoperative morbidity and mortality.

FEVAR enables surgical treatment in a patient group that, because of comorbidities, may not be suited for open repair.^[@bibr11-2050312113519986][@bibr12-2050312113519986]--[@bibr13-2050312113519986]^ It has been shown that FEVAR for juxtarenal aneurysms and EVAR for infrarenal aneurysms are associated with reduced short-term mortality in comparison with open repair.^[@bibr14-2050312113519986],[@bibr32-2050312113519986],[@bibr33-2050312113519986]^ In the present study, comparable short- and mid-term survival was found in the FEVAR and EVAR groups. This might, again, be explained by the more stringent patient selection in the FEVAR group. In addition, there was no difference in reintervention rate between the EVAR and FEVAR groups. Crude 2-year mortality data in the FEVAR patients in the present study was 10%. This is in concordance with a previous prospective study including 38 patients undergoing FEVAR, with median time of follow-up of 25 months, in which all-cause mortality was 13%.^[@bibr34-2050312113519986]^ Crude 30-day mortality in the EVAR group presented is in concordance with the results of previous large randomized trials.^[@bibr33-2050312113519986],[@bibr35-2050312113519986][@bibr36-2050312113519986]--[@bibr37-2050312113519986]^ According to the Kaplan--Meier curve presented in this study, mid-term mortality in the EVAR group was similar to the mortality in previous large randomized trials.^[@bibr33-2050312113519986],[@bibr35-2050312113519986][@bibr36-2050312113519986]--[@bibr38-2050312113519986]^

This study demonstrated a high cardiovascular medication coverage in both the FEVAR and the EVAR groups at admission. There was no significant difference between the groups regarding the number of patients with ongoing treatment with antiplatelet drugs, lipid-lowering agents, or vitamin K antagonists. Pharmacological optimization is considered an essential part of the preoperative evaluation in AAA patients and is at our unit performed by a specialist in vascular medicine. Such preoperative individual assessment prior to elective AAA repair has been shown to uncover a substantial proportion of patients with suboptimal cardiovascular medication and furthermore to decrease postoperative short- and mid-term morbidity due to better cardiopulmonary medication.^[@bibr5-2050312113519986],[@bibr6-2050312113519986],[@bibr10-2050312113519986],[@bibr39-2050312113519986]^

Besides its retrospective design, one limitation of the study was that the percentage of patients turned down for both FEVAR and EVAR, and the reasons why during the study period were unknown. Such information would have strengthened this study. Another study limitation was that patients were postoperatively referred to general health care physicians. Therefore, we do not know to what extent the optimized cardiovascular medication in each patient at discharge was maintained, a factor that might well influence postoperative mortality.

Conclusion {#section21-2050312113519986}
==========

Mid-term survival in patients with juxtarenal aneurysmal disease undergoing elective FEVAR was comparable to patients undergoing elective standard EVAR. This might be explained by careful patient selection and medical optimization.
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